VAK 694

Drug Profile

VAK 694

Alternative Names: NVP-VAK694; VAK694

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antiallergics; Antibodies
  • Mechanism of Action Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 31 Oct 2011 Novartis completes a phase II trial in Seasonal allergic rhinitis in United Kingdom (NCT01018693)
  • 28 Feb 2011 Novartis completes a phase II trial in Seasonal allergic rhinitis in USA & Canada (NCT00929968)
  • 12 May 2010 Novartis completes enrolment in its phase II trial (NCT01018693) for Seasonal allergic rhinitis in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top